A Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers

Trial Profile

A Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2017

At a glance

  • Drugs Marijuana (Primary)
  • Indications Neuropathic pain; Pain
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Status changed from recruiting to completed, according to a Tetra Bio Pharma media release.
    • 07 Jun 2017 According to a Tetra Bio Pharma media release, the company has submitted a report on the safety and pharmacokinetics of PPP001 (smokeable marijuana) to Health Canada.
    • 23 Feb 2017 According to a Tetra Bio Pharma media release, data from this trial will be used to finalize the design of its Phase II-III clinical trial of PPP001 in cancer patients with uncontrolled pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top